FEASTERVILLE, Pa.--(BUSINESS WIRE)--Nov. 18, 2003--For the sixth consecutive reporting cycle, managed care pharmacy directors ranked GlaxoSmithKline's disease management programs as the best in the pharmaceutical industry, according to Cognet-X Inc. data. GlaxoSmithKline ranked first in the Disease/Health Management Programs assessment category in the first-quarter ranking period of the twice-yearly Corporate Assessment Total Rankings component of Cognet-X's PAR-Rx (Promotional Assessment Research) Report(TM). Since PAR-Rx Report launched in January 2001, GlaxoSmithKline has ranked first in this assessment category.
Managed care executives appreciate disease management programs that help physicians and patients keep serious, often chronic, conditions such as asthma, diabetes and heart disease under control. If untreated or under-treated, these conditions can lead to life-threatening emergencies and costly medical bills, including hospitalizations.
PAR-Rx panelists praised GlaxoSmithKline programs on asthma, diabetes, behavioral health, migraine and appropriate antibiotic use. Pharmacy directors also expressed their satisfaction with the comprehensive nature of the company's offerings.
"Great educational materials provided to members and (health care) providers. Materials explained to members what triggers a migraine and ways to avoid the triggers as well as the migraine itself," one panelist noted.
Said another, "Our asthma management team uses a management program supported by GSK. We have access to patient hand-outs, and they are no charge to us and enable us to offer some asthma education to high-risk members."
Pfizer, previously ranked eighth, moved up to second place in the 3Q 2003 assessment period. Pfizer's offerings include programs for diseases and conditions such as high cholesterol, diabetes, asthma, Alzheimer's disease, depression and arthritis.
"Excellent selection and very complete, well thought-out group of programs and/or components," one pharmacy director told Cognet-X.
Hoffmann-La Roche Inc. and Novo Nordisk Pharmaceuticals rose in the rankings, finishing within the top 10 in this category. Roche received high marks for its Pegassist(TM) program for Hepatitis C patients; Novo Nordisk garnered praise for its "excellent ongoing program support for patients and health care providers regarding diabetes education."
The complete top 10 corporations in terms of Disease/Health Management Programs rankings were as follows:
1. GlaxoSmithKline 2. Pfizer Inc. 3. Merck & Co. Inc. 4. AstraZeneca PLC 5. Aventis Pharma AG 6. (tie) Novartis Pharmaceuticals Corp. and Wyeth 7. TAP Pharmaceuticals Inc. 8. Hoffmann-La Roche Inc. 9. Novo Nordisk Pharmaceuticals 10. Abbott Laboratories
About the PAR-Rx Report
Cognet-X's PAR-Rx Report is a year-round service that provides the pharmaceutical industry with real-time, Internet-based competitive intelligence on pharmaceutical company promotion to influential managed care pharmacy directors.
The Report offers Cognet-X clients the ability to evaluate and analyze variable differences that are critically important to their decision-making process. The Report collects comprehensive data that can be segmented and analyzed to provide clients with "21st-Century solutions to their 21st-Century challenges."
Cognet-X offers the pharmaceutical industry market research, consulting and software development that help companies build and refine their relationships with numerous customer bases, including the managed care community. Based in Bucks County, Pennsylvania, Cognet-X is privately held and employee-owned.
For more information on the PAR-Rx Report or other valuable Cognet-X products, please contact James A. Barone (extension 102) or Rick Bourland (extension 103) at (215) 396-8300 or via e-mail at firstname.lastname@example.org or email@example.com.
Cognet-X Inc. James A. Barone, 215-396-8300 ext. 102 e-mail: firstname.lastname@example.org or Rick Bourland, 215-396-8300 ext. 103 e-mail: email@example.com
Source: Cognet-X Inc.